See more : Natura &Co Holding S.A. (NTCO) Income Statement Analysis – Financial Results
Complete financial analysis of Hanmi Pharm. Co., Ltd. (128940.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hanmi Pharm. Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Anew Medical, Inc. (WENA) Income Statement Analysis – Financial Results
- Bufab AB (publ) (BUFAB.ST) Income Statement Analysis – Financial Results
- Probe Gold Inc. (V46.F) Income Statement Analysis – Financial Results
- Asia Dragon Trust plc (DGN.L) Income Statement Analysis – Financial Results
- RS Public Company Limited (RS-R.BK) Income Statement Analysis – Financial Results
Hanmi Pharm. Co., Ltd. (128940.KS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.hanmipharm.com
About Hanmi Pharm. Co., Ltd.
Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,490.89B | 1,331.55B | 1,203.19B | 1,075.85B | 1,113.65B | 1,015.96B | 916.59B | 882.72B | 1,317.53B | 761.28B | 730.13B | 674.01B | 606.19B | 337.38B |
| Cost of Revenue | 661.64B | 612.99B | 570.43B | 494.94B | 481.17B | 475.05B | 398.18B | 421.87B | 398.25B | 338.78B | 313.68B | 279.33B | 271.86B | 142.35B |
| Gross Profit | 829.25B | 718.55B | 632.75B | 580.92B | 632.48B | 540.92B | 518.40B | 460.86B | 919.28B | 422.50B | 416.45B | 394.68B | 334.34B | 195.03B |
| Gross Profit Ratio | 55.62% | 53.96% | 52.59% | 54.00% | 56.79% | 53.24% | 56.56% | 52.21% | 69.77% | 55.50% | 57.04% | 58.56% | 55.15% | 57.81% |
| Research & Development | 192.23B | 154.32B | 146.03B | 212.39B | 194.29B | 165.91B | 151.29B | 142.89B | 167.99B | 135.17B | 94.97B | 79.99B | 70.52B | 32.08B |
| General & Administrative | 65.22B | 61.33B | 61.79B | 47.48B | 62.61B | 58.86B | 58.39B | 47.53B | 54.72B | 53.03B | 57.92B | 64.07B | 61.12B | 54.33B |
| Selling & Marketing | 183.03B | 172.31B | 151.59B | 134.46B | 128.35B | 110.90B | 111.42B | 124.50B | 260.56B | 80.95B | 93.00B | 89.56B | 69.66B | 47.87B |
| SG&A | 422.60B | 233.63B | 213.38B | 181.94B | 190.96B | 169.76B | 169.81B | 172.03B | 315.28B | 133.97B | 150.93B | 153.63B | 130.78B | 102.20B |
| Other Expenses | 0.00 | 172.51B | 147.93B | 137.61B | 143.36B | 121.67B | -4.11B | 12.12B | 17.45B | 11.64B | 6.93B | 2.53B | 8.77M | 757.61M |
| Operating Expenses | 608.56B | 560.46B | 507.34B | 531.94B | 528.60B | 457.34B | 436.24B | 434.08B | 707.48B | 388.05B | 354.56B | 346.54B | 310.06B | 198.83B |
| Cost & Expenses | 1,270.20B | 1,173.46B | 1,077.77B | 1,026.88B | 1,009.77B | 932.39B | 834.42B | 855.95B | 1,105.73B | 726.83B | 668.24B | 625.86B | 581.92B | 341.18B |
| Interest Income | 4.62B | 7.86B | 5.72B | 4.38B | 4.42B | 4.25B | 3.75B | 2.99B | 1.01B | 3.60B | 2.67B | 1.98B | 1.13B | 581.02M |
| Interest Expense | 28.51B | 22.65B | 16.58B | 24.87B | 25.00B | 19.41B | 10.70B | 10.07B | 12.27B | 12.09B | 14.78B | 17.45B | 16.91B | 8.10B |
| Depreciation & Amortization | 98.45B | 96.84B | 89.09B | 61.34B | 55.41B | 47.12B | 36.97B | 38.77B | 50.13B | 25.39B | 27.09B | 33.51B | 35.70B | 19.17B |
| EBITDA | 323.34B | 249.04B | 209.36B | 108.34B | 163.68B | 116.89B | 106.52B | 56.85B | 271.98B | 59.84B | 88.98B | 83.35B | 59.06B | 20.07B |
| EBITDA Ratio | 21.69% | 19.23% | 17.66% | 11.09% | 15.06% | 11.69% | 11.72% | 11.04% | 21.66% | 10.09% | 13.61% | 12.77% | 10.30% | 5.95% |
| Operating Income | 224.88B | 158.09B | 125.42B | 48.98B | 103.88B | 83.57B | 82.16B | 26.77B | 211.80B | 34.45B | 61.90B | 48.14B | 22.68B | -3.80B |
| Operating Income Ratio | 15.08% | 11.87% | 10.42% | 4.55% | 9.33% | 8.23% | 8.96% | 3.03% | 16.08% | 4.53% | 8.48% | 7.14% | 3.74% | -1.13% |
| Total Other Income/Expenses | -30.92B | -37.08B | -21.72B | -26.85B | -20.61B | -33.22B | -23.31B | -18.77B | -2.22B | 2.01B | -7.07B | -15.94B | -16.23B | -9.24B |
| Income Before Tax | 193.97B | 121.01B | 103.70B | 22.13B | 83.27B | 50.35B | 58.85B | 8.00B | 209.58B | 36.46B | 54.83B | 32.20B | 6.45B | -13.04B |
| Income Before Tax Ratio | 13.01% | 9.09% | 8.62% | 2.06% | 7.48% | 4.96% | 6.42% | 0.91% | 15.91% | 4.79% | 7.51% | 4.78% | 1.06% | -3.86% |
| Income Tax Expense | 28.60B | 19.45B | 22.22B | 4.84B | 19.40B | 16.20B | -10.12B | -22.30B | 47.52B | -6.83B | 4.29B | 3.45B | 1.02B | -4.10B |
| Net Income | 146.23B | 82.79B | 67.03B | 17.29B | 52.11B | 34.16B | 60.43B | 23.33B | 154.44B | 35.51B | 43.93B | 22.64B | 1.29B | -12.70B |
| Net Income Ratio | 9.81% | 6.22% | 5.57% | 1.61% | 4.68% | 3.36% | 6.59% | 2.64% | 11.72% | 4.66% | 6.02% | 3.36% | 0.21% | -3.76% |
| EPS | 11.52K | 6.52K | 5.27K | 1.36K | 4.01K | 2.74K | 4.97K | 1.86K | 12.31K | 2.79K | 3.59K | 1.98K | 118.42 | -1.16K |
| EPS Diluted | 11.52K | 6.52K | 5.27K | 1.36K | 4.01K | 2.74K | 4.97K | 1.86K | 12.31K | 2.79K | 3.59K | 1.98K | 118.42 | -1.16K |
| Weighted Avg Shares Out | 12.69M | 12.70M | 12.72M | 12.73M | 13.00M | 12.49M | 12.17M | 12.54M | 12.55M | 12.71M | 12.22M | 11.44M | 10.90M | 10.90M |
| Weighted Avg Shares Out (Dil) | 12.69M | 12.70M | 12.72M | 12.73M | 13.00M | 12.49M | 12.17M | 12.54M | 12.55M | 12.71M | 12.22M | 11.44M | 10.90M | 10.90M |
No news found for: 128940.KS
Source: https://incomestatements.info
Category: Stock Reports